Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B

Current Medical Research and Opinion

Volumn 33, Issue 3, 2017, Pages 495-504

  Wei, Lai ^a   Kao, Jia Horng ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis B; long term benefits; long term safety; nucleoside analogues; nucleotide analogues; outcomes

Indexed keywords

NUCLEOSIDE ANALOG; NUCLEOTIDE; ANTIVIRUS AGENT; NUCLEOSIDE;

CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MEDLINE; MORTALITY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; RETROSPECTIVE STUDIES;

EID: 85011391275     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1264932     Document Type: Review

References (50)

1. World Health Organization. Hepatitis B. Fact Sheet No. 204. Available at:http://www.who.int/mediacentre/factsheets/fs204/en/#, July 2016
2. Liaw YF., Antiviral therapy of chronic hepatitis B:opportunities and challenges in Asia. J Hepatol 2009;51:403-10
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of chronic hepatitis Br J Hepatol 2009;50:227-42
4. Lavanchy D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
5. Liaw YF, Chu CM., Hepatitis B virus infection. Lancet 2009;373:582-92
6. Lok AS, McMahon BJ., Chronic hepatitis B:update 2009. Hepatology 2009;50:661-2
7. Ott JJ, Stevens GA, Groeger J, Wiersma ST., Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19
8. Li CZ, Hu JJ, Xue JY, et al. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol 2014;20:9486-96
9. Liu CJ, Kao JH., Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to J. Semin Liver Dis 2013;33:97-102
10. Cui Y, Jia J., Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 2013;28(Suppl 1):7-10
11. Sun J, Hou JL., Management of chronic hepatitis B:experience from China. J Viral Hepat 2010;17(Suppl 1):10-17
12. Jia JD, Zhuang H., [The overview of the seminar on chronic hepatitis B]. Chin J Hepatol 2004;12:698-9
13. Menéndez-Arias L, Alvarez M, Pacheco B., Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase:mechanism of action and resistance. Curr Opin Virol 2014;8C:1-9
14. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int 2016;10:1-98
15. European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
16. Fung J, Lai CL, Seto WK, Yuen MF., Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011;66:2715-25
17. Gish R, Jia JD, Locarnini S, Zoulim F., Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012;12:341-53
18. Ma H, Jia J., Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue? Liver Int 2013;33(Suppl 1):133-6
19. Chotiyaputta W, Hongthanakorn C, Oberhelman K, et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012;19:205-12
20. Xie F, Yan L, Lu J, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure:meta-analysis. PLoS One 2013;8:e54773
21. Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications:a meta-analysis. Virol J 2011;8:72
22. Chotiyaputta W, Lok AS., Endpoints of hepatitis B treatment. J Viral Hepat 2010;17:675-84
23. Su TH, Kao JH., Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol 2015;9:141-54
24. Papatheodoridis GV, Chan HL, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67
25. Kim SS, Hwang JC, Lim SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients:comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223-33
26. Tsai MC, Yu HC, Hung CH, et al. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol 2014;29:568-75
27. Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-61
28. Kim MN, Kim SU, Kim BK, et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int 2014;34:1216-23
29. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107
30. Kobashi H, Miyake Y, Ikeda F, et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-16
31. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B–a nationwide cohort study. Gastroenterology 2014;147:143-51.e5
32. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
33. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-6
34. Lim SG, Aung MO, Mak B, et al. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. J Clin Gastroenterol 2011;45:818-23
35. Hashimoto Y, Suzuki F, Hirakawa M, et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 2010;82:684-91
36. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
37. Akuta N, Suzuki F, Suzuki Y, et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B:an 8-year follow-up study. J Med Virol 2005;75:491-8
38. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:a multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-84
39. Miquel M, Núñez O, Trapero-Marugán M, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013;12:205-12
40. Köklü S, Tuna Y, Gülsen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:88-94
41. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet 2013;381:468-75
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
43. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9
44. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91
45. Gaia S, Marzano A, Smedile A, et al. Four years of treatment with lamivudine:clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004;20:281-7
46. Niro GA, Ippolito AM, Fontana R, et al. Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. J Viral Hepat 2013;20:502-9
47. Singal AK, Salameh H, Kuo YF, Fontana RJ., Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013;38:98-106
48. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A., Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review. J Hepatol 2010;53:348-56
49. Ye XG, Su QM., Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis:meta-analysis. World J Gastroenterol 2013;19:6665-78
50. Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B:a cohort study of 53,500 subjects. Hepatology 2015;62:684-93